I. MODIFIED AGREEMENTS

Biotech Co.*
(Country;
Symbol)

Pharma Co.
(Country)

Change from original agreement

Terms/Details (Date)


Axiom Biotechnologies Inc.*

UCB SA (Belgium)

Extended collaboration to discover drugs for the treatment of allergic rhinitis

Terms include an up-front payment, research support, milestone payments and bonuses; the one-year contract is extendable for a second year (4/2)

ChemCodes
Inc.*

GlaxoSmithKline plc (UK)

Expanded technology license agreement

The agreement extends a previous agreement centered on chemistry to include biological screening processes; the ex- tension allows ChemCodes to leverage its technology platform for drug discovery (5/6)

Genmab A/S (Denmark; CSE:GEN)

F. Hoffmann-La Roche Ltd. (Switzerland)

Expanded agreement to create and develop human antibody therapeutics for Roche using the UltiMAb platform technology licensed from Medarex Inc.

The expanded project involves a number of new disease targets; Roche made a $20M equity investment in Genmab (6/6)

Isis Pharmaceuticals Inc. (ISIS)

Eli Lilly and Co.

Expanded agreement for Isis' antisense technology, opening the deal up to include specific gene targets for cancer and adding to its total value

Lilly licensed Affinitac in the initial agreement that was worth as much as $400M; the expansion includes work on several preclinical antisense compounds; specifics of the value added to the deal were not disclosed (6/18)

Neurocrine Biosciences
Inc.
(NBIX)

Wyeth (formerly American Home Products Corp.)

Extended research collaboration focused on the excitatory amino acid transporter subtype, EAAT-3, with applications to treat schizophrenia, Alzheimer's disease and other nervous system disorders

Wyeth will provide extended funding for an additional year; Neurocrine is entitled to receive payment for milestones reached and worldwide royalties on commercial sales of products that result (5/1)

Palatin Technologies Inc. (AMEX:PTN)

Mallinckrodt Inc. (division of Tyco Healthcare; Bermuda)

Amended agreement for the marketing of Palatin's infection imaging agent, LeuTech

Mallinckrodt committed up to an additional $3.2M to cover half of Palatin's estimated expenses associated with completing the FDA review process (5/15)

Pharmacopeia Inc. (PCOP)

NV Organon (the Netherlands)

Expanded drug discovery collaboration to include initiating a medicinal chemistry optimization program to identify candidates for development by Organon

Pharmacopeia will commit its medicinal chemistry, biology and ADME knowledge to identify optimized compounds for development (5/9)

Pharsight Corp. (PHST)

Pfizer Inc.

Expanded clinical development partnership in which Pharsight has supplied technology to Pfizer's Sandwich, UK, and Ann Arbor, Mich., sites since 1998

The new agreement expands the relationship to Pfizer's Groton, Conn., and La Jolla, Calif., sites; terms were not disclosed (6/12)

Prolifix Ltd.* (UK)

Novuspharma SpA (Italy)

Acquisition of rights to the anti-angiogenic research project in which the companies were collaborating since September 2000

The alliance conducted research into a series of Prolifix's compounds with anti-angiogenic properties, specifically those inhibiting hypoxia-inducible factor Ia; NovusPharma now has rights to the research, compounds and associated intellectual property; the acquisition price was not disclosed (5/15)

Structural Bioinformatics Inc.*

Johnson & Johnson Pharmaceutical Research & Development LLC (unit of Johnson & Johnson)

Expanded collaboration for more structural proteomics services in support of PRD's drug discovery programs using X-ray crystallography and drug-protein co-crystallization technologies for PRD proprietary compounds

Financial terms were not disclosed (4/18)

Telik Inc.
(TELK)

Sanwa Kagaku Kenkyusho Co. Ltd. (Japan)

Expanded collaboration on drug candidates to treat inflammatory diseases

Sanwa will provide funding for the research and have marketing rights in Japan and certain other Asian countries to any resulting compounds; Telik has rights in North and South America, with the companies jointly owning rights in the rest of the world (4/19)

ViroLogic Inc. (VLGC)

Pfizer Inc.

Expanded agreement to use ViroLogic's HIV-resistance testing technology in Pfizer's HIV drug discovery and development programs

The agreement covers work performed for all of Pfizer's global research and development sites worldwide; financial terms were not disclosed (6/18)

ViroPharma
Inc.
(VPHM)

Wyeth (formerly American Home Products Corp.)

Extended agreement for two years related to the screening phase of a hepatitis C drug

The companies will continue to split costs evenly for research and development work being done at both companies (6/19)

II. TERMINATED AGREEMENTS

Amgen Inc. (AMGN)

Roche Holding AG (Switzerland)

Agreement in which Amgen regains control over European assets and business related to two white-cell boosters that are sold in the U.S. under the names Neupogen and Neulasta

Amgen regains the rights to filgrastim (Neupogen) and pegfilgrastim (Neulasta) in the European Union, Switzerland and Norway; Amgen paid $137.5M to gain control over the assets (5/8)

Corvas International
Inc.
(CVAS)

Pfizer Inc.

Terminated agreement to develop Corvas' anti-inflammatory product, rNIF

Pfizer returned the rights to Corvas after a Phase IIb analysis showed the product had no effect on recovery in acute ischemic stroke patients; Corvas had received $4.4M in the deal that was worth a potential $31.4M (6/17)

DUSA Pharmaceuticals Inc. (DUSA)

Schering AG (Germany)

Terminated marketing and development agreement for Levulan PDT in dermatology

Schering terminated the agreement, and DUSA will reacquire all rights within 12 months (6/7)

Immune
Network Ltd.*
(Canada)

Bridge Pharma Inc.

Terminated joint venture agreement that gave Immune Network a 5% royalty interest in certain Bridge Pharma revenues

Bridge's asthma and eczema projects were part of the joint venture with Immune Network (5/23)

Indevus Pharmaceuticals Inc. (IDEV)

Pfizer Inc.

Terminated agreement for pagoclone, a late-stage drug for general anxiety and panic

Pfizer is returning all rights to Indevus because pagoclone had failed to meet primary endpoints in several studies (6/7)

Neose Technologies
Inc.
(NTEC)

Wyeth (formerly American Home Products Corp.)

Wyeth stopped development for P-selectin glycoprotein ligand to treat myocardial infarction, but will consider other indications

Neose will miss out on research and development support and potential milestones (5/10)


Notes:

# The information in the chart does not cover agreements between biotech companies or agricultural agreements.

* Private companies are indicated with an asterisk; unless otherwise noted, stock symbols listed are on the Nasdaq market.

This chart includes a collaboration that occurred before April 18, 2002, but it was not listed in the previous chart.

AMEX = American Stock Exchange; CSE = Copenhagen Stock Exchange

No Comments